Moderna’s updated RSV vaccine disappoints with only 50% efficacy

Mod­er­na re­port­ed that its vac­cine was 50% ef­fec­tive at pre­vent­ing low­er res­pi­ra­to­ry dis­ease fol­low­ing RSV in­fec­tion, falling short of num­bers re­port­ed by GSK and Pfiz­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.